ReNeuron Group (LSE:RENE) Momentum Rank : 0 (As of May. 14, 2024)

View and export this data going back to 2005. Start your Free Trial

What is ReNeuron Group Momentum Rank?

ReNeuron Group has the Momentum Rank of 0.

For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.

Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.

For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.

ReNeuron Group Momentum Rank Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

ReNeuron Group (LSE:RENE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (LSE:RENE) » Definitions » Momentum Rank

Comparable Companies

Traded in Other Exchanges

RNUGF:USA RENE.GB:UK RQE1:Germany

Address

Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY

Website

https://www.reneuron.com

ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.